QR678 & QR678 Neo Hair Growth Formulations: A Cellular Toxicity & Animal Efficacy Study

Abstract

Background: Current treatment modalities are limited in their approach and success for hair loss. QR 678 & QR 678 Neo are new formulations, consisting of a combination of growth factors and peptides. This study demonstrates safety analysis of QR 678 & QR 678 Neo formulation, using in vitro cytotoxicity assay and in vivo animal efficacy. Methods: Factors including vascular endothelial growth factor, basic fibroblast growth factor, insulin-like growth factor-1, keratinocyte growth factor, and copper tripeptide 1 (QR 678) or their biomimetic peptides (QR678 Neo) were suspended in a sterile injectable vehicle. The 3-2,5-diphenyl tetrazolium bromide assay was used to explore the cytotoxic effects of each factor used in the compositions in human keratinocyte cell and human fibroblast cell assays. An in vivo analysis, wherein study animals were given intradermal QR 678 & QR 678 Neo injections, was conducted to assess whether the formulations produce hair growth. Also, hair follicle viability was checked by intradermal injection of the pharmaceutical compositions in secondary alopecia. Results: In both formulations, a positive response was observed with respect to the number of mice exhibiting hair growth at the injection sites. The injections caused retention of hair in a 0.25-cm radius around the injection site. On cytotoxicity study, all the factors were found to be safe in human keratinocyte cell and human fibroblast cell assay. A positive response was demonstrated in animals on treatment with the chemotherapeutic agent. Conclusions: Intradermal injections of QR 678 & QR 678 Neo hair growth factor formulations are a safe and efficacious option for alopecia. Results seem encouraging enough to warrant a trial in humans with secondary alopecia, post cancer chemotherapy.

Growth Factors VEGF-A165 and FGF-2 as Multifunctional Biomolecules Governing Cell Adhesion and Proliferation

“…FGF-2 also proved its efficacy in the treatment of oral lichen planus [25] or vitiligo [26]. Animal studies also proved that FGF-2 is promising for regenerative therapy of spinal cord injury [27], of liver injury and liver diseases [28], or for treatment of alopecia [29]. It also enhanced the tendon-to-bone healing in a rabbit model [30].…”

A newer approach in the treatment of seborrheic dermatitis with QR678® and QR678 Neo®—A prospective pilot study

“…26 An animal study was the first to demonstrate safety and effectiveness, and it revealed that they were largely free from negative effects. 27 Additionally, a 1000-patient open-label, prospective, single-arm interventional pilot research using the QR678 Neo® revealed that the formulation of several growth factors in QR678® and QR678 Neo® is equally effective in treating both male and female pattern hair loss. 26 The formulation QR678 Neo® contains hair growth factors, vitamins and minerals, which also have anti-inflammatory action.…”

Evaluation of the safety and effectiveness of intradermal administration of QR678 Neo®hair growth factor formulation: A phase‐IV, open‐label, single‐arm multi‐ethnicity clinical trial

“…16 QR678 Neo ® preparation is a derived from plant source polypeptides and formulated such that biologically replicates the activity of QR678 ® and contains a specific concentration of Sh-polypeptide-9 (bio-mimicking VEGF), Sh-oligopeptide-2 (bio-mimicking IGF-1), Sh-polypeptide-3 (bio-mimicking KGF), Sh-polypeptide-1 (biomimicking bFGF), copper tripeptide, and Sh-oligopeptide-4 (biomimicking thymosin β4) dissolved in a sterilized soluble solution. 17 An animal trial was first conducted to evaluate its safety and efficacy which was found to be over all free from side effects. In addition, an open-label interventional and clinical study was carried out in males using QR678 Neo ® .…”

“…QR678 Neo ® preparation is a derived from plant source polypeptides and formulated such that biologically replicates the activity of QR678 ® and contains a specific concentration of Sh‐polypeptide‐9 (bio‐mimicking VEGF), Sh‐oligopeptide‐2 (bio‐mimicking IGF‐1), Sh‐polypeptide‐3 (bio‐mimicking KGF), Sh‐polypeptide‐1 (bio‐mimicking bFGF), copper tripeptide, and Sh‐oligopeptide‐4 (bio‐mimicking thymosin β4) dissolved in a sterilized soluble solution 17 …”